Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo-Reference-Cited by-同舟云学术

Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo

Published:2014-11-12 Issue:1 Volume:64 Page:41-51
ISSN:1023-3830
Container-title:Inflammation Research
language:en
Short-container-title:Inflamm. Res.

Author:

Tanimoto Atsuo,Ogawa Yoshihiro,Oki Chika,Kimoto Yukari,Nozawa Keisuke,Amano Wataru,Noji Satoru,Shiozaki Makoto,Matsuo Akira,Shinozaki Yuichi,Matsushita Mutsuyoshi

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology,Immunology

Link

http://link.springer.com/article/10.1007/s00011-014-0782-9/fulltext.html

Reference21 articles.

1. Boulay JL, O’Shea JJ, Paul WE. Molecular phylogeny within type I cytokines and their cognate receptors. Immunity. 2003;19:159–63.

2. Yamaoka K, Saharinen P, Pesu M, Holt VE 3rd, Silvennoinen O, O’Shea JJ. The Janus kinases (Jaks). Genome Biol. 2004;5:253.

3. O’Shea JJ, Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity. 2012;36:542–50.

4. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008;26:127–32.

5. Tanaka Y, Suzuki M, Nakamura H, Toyoizumi S, Zwillich SH, Tofacitinib Study Investigators. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken). 2011;63:1150–8.

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Januskinaseinhibitoren für dermatologische Erkrankungen;Die Dermatologie;2024-08-30

2. Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials;The Lancet;2024-08

3. Janus Kinases and Autoimmunity: Bridging Pathways to Therapy;International Journal of Drug Discovery and Pharmacology;2024-06-05

4. Involvement of Janus kinase‐dependent Bcl‐xL overexpression in steroid resistance of group 2 innate lymphoid cells in asthma;Immunology;2024-05-24

5. Anti-inflammatory and anti-fibrotic effects of topical pan-JAK inhibitor in a chronic graft-versus- host disease model mouse;2024-04-19